In a public-private partnership, Cancer Research Technologies and the Institute of Cancer Research registered patent no. US2016355510A1 (1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4h-pyrido [2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as Raf inhibitors for the treatment of cancer) in 2013 (Springer et al., 2013). The gene discussed is RAF1; the disease is cancer.